



MEDICAL TIPS

DIABIZ Tablets

Issue X, No.39, 2023

Effectiveness of Dapagliflozin as add-on to Metformin alone or Metformin with other oral antidiabetic drug classes- A Multicenter, Retrospective, Real-World Evidence Study.

Sethi B et al. Diabetes 2023; 72 (1): 889-P

- The current Electronic Medical Record based, retrospective, multicentre study in adult Type-2 Diabetes Mellitus patients inadequately controlled on existing antidiabetic therapy was conducted to evaluate the efficacy of add-on dapagliflozin in the present real-world settings.
- 3616 patients from 478 centres were included where most patients had received DAPA + MET + at least one oral anti-diabetic drug (OAD), while the rest received DAPA + MET alone.
- The glycated haemoglobin (HbA1c), body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were evaluated as treatment-related outcomes at 60 days and 140 days after adding DAPA.
- For the DAPA + MET group a significant change was noted for all parameters except SBP and DBP and for the DAPA + MET + OAD group a significant change was noted for all parameters except BMI.

Dapagliflozin showed significant improvement in glycaemic parameters, BMI and BP when added to metformin, with or without other OADs in real-world.



